International Journal of Hematology

DOI: 10.1007/s12185-013-1293-0 Pages: 306-312

Multiple myeloma-initiating cells

1. Osaka University Graduate School of Medicine, Departments of Functional Diagnostic Science and Cancer Stem Cell Biology

Correspondence to:
Naoki Hosen
Tel: +81-6-68793676
Fax: +81-6-68793676
Email: hnaoki@imed3.med.osaka-u.ac.jp

Close

Abstract

Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells. As in other cancers, MM plasma cells are thought to be derived from MM-initiating cells, although these remain unidentified. MM patients harbor phenotypic CD19+ B cells expressing the immunoglobulin gene sequence and the idiotype unique to the individual myeloma clone. Some previous studies have reported that CD19+ clonotypic B cells can serve as MM-initiating cells. However, we and another group have recently showed that CD19+ B cells from many MM patients do not reconstitute MM disease upon transplantation into NOD/SCID IL2Rγc−/− mice. In the SCID-rab and SCID-hu models, which enable engraftment of human MM in vivo, CD19CD38++ plasma cells engrafted and rapidly propagated MM, while engraftment of CD19+ B cells was not detected. Both CD138 and CD138+ plasma cells have the potential to propagate MM clones in vivo in the absence of CD19+ B cells. Distinct from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, MM-initiating cells are derived from plasma cells, which are terminally differentiated cells. An improved understanding of how the bone marrow microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model, is thus now essential.

This article is freely available, click here to access the full text/PDF

Share the Knowledge